anti-VEGF drugs

(redirected from pegaptanib sodium)

anti-VEGF drugs 

Drugs which bind to VEGF receptors without causing activation, thus blocking the production of new blood vessels and enhanced vessel permeability by the vascular endothelial growth factor (VEGF). They are used in the treatment of some forms of cancer (administered intravenously), and injected intravitreally in the treatment of choroidal neovascularization, retinal venous occlusion, and macular oedema. Examples: bevacizumab, pegaptanib sodium, ranibizumab. Syn. angiogenesis inhibitors. See age-related macular degeneration; diabetic retinopathy; VEGF.
References in periodicals archive ?
Agents approved by the FDA for intravitreal injection to treat neovascular AMD include ranibizumab (Lucentis: Genentech, South San Francisco, CA) and pegaptanib sodium (Macugen; Eyetech Pharmaceuticals, New York, NY).
Currently used intravitreal drugs for the treatment of retinal diseases include triamcinolone acetonide (Kenalog-40, Bristol-Myers Squibb, Peapack, NJ, USA), pegaptanib sodium (Macugen, Eyetech-OSI, New York, USA), bevacizumab (Avastin, Genenetech, San Francisco, CA, USA), and ranibizumab (Lucentis, Genentech, San Francisco, CA, USA).
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Pegaptanib sodium ('Macugen', Eyetech, New York) was the first treatment of this kind to be approved by the Food and Drug Agency (FDA) in the US in 2004.
Pegaptanib sodium for the treatment of neovascular age related macular degeneration; a review.
Pegaptanib sodium (Macugen), which is currently approved for the treatment of macular degeneration, works by specifically blocking one of the six human isoforms of vascular endothelial growth factor (VEGF).
Pegaptanib sodium (Macugen), which runs about $1,000 per dose, also may be prescribed every six weeks for the two-year period.
Among these drugs is pegaptanib sodium (Macugen), approved by the FDA in December 2004.
Pegaptanib sodium injection (Macugen) was approved by FDA in 2004.